Camlipixant

凯立匹生

Report date: 2026/04/10 20:01:49
NME

Base Information

Drug NameCamlipixant
Drug Alias NameBLU-5937BLU 5937NEO 5937AZ 13410937GSK-5464714 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionP2X purinoceptor 3 antagonists
TargetsP2X purinoceptor 3
Therapy Area/IndicationsPruritusDermatitis, AtopicCough +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[23] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline PlcBellus Health IncGeorge(Beijing)Clinical Research Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsPruritusDermatitis, AtopicCough +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A